Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature

Skin Therapy Letter-Family Practice Edition

关键词: atopic dermatitis;    dupilumab;    eczema;    IL-4Rα;    IL-4;    IL-13;    monoclonal antibody;    EASI-50;    EASI-75;    SCORAD;   

DOI  :  

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Atopic dermatitis results when aberrant barrier function and immune activation occur within the skin. Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Of these, dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown the greatest promise. Clinical trials of systemic dupilumab in moderate-to-severe atopic dermatitis have demonstrated marked improvement in patient symptoms, including pruritus and clinically visible disease. Importantly, dupilumab treatment has been correlated with changes in the molecular signature of diseased skin, with reduction of both inflammatory and proliferative markers. Dupilumab recently received US FDA breakthrough therapy designation for atopic dermatitis, with ongoing trials in both adult and pediatric populations. Altogether, dupilumab has shed new light on the pathomechanisms driving atopic dermatitis and is making unprecedented advances towards highly effective control of this debilitating disease.

【 授权许可】

Unknown